PFIZER INC.

CD47 inhibitor drugs, targeting cancer cell evasion, are in advanced clinical trials, with magrolimab and evorpacept leading. Combination therapies are key, aiming to enhance efficacy and overcome resistance. Market growth is driven by rising cancer incidence and immunotherapy use, attracting significant investments and partnerships. Challenges include managing toxicity and demonstrating therapeutic advantages. The field is rapidly expanding, with global competition intensifying.

Worldwide Clinical Trials appoints Alessandra Vignola as president of cardiovascular and metabolic business unit, leveraging her 30+ years of experience in pharmaceutical and clinical research to drive advancements in diabetes, obesity, and cardiovascular-kidney-metabolic diseases.

Faruqi & Faruqi, LLP's James (Josh) Wilson encourages investors who suffered losses exceeding $100,000 in Moderna between January 18, 2023, and June 25, 2024, to contact him directly to discuss their options. The firm is investigating potential claims against Moderna and reminds investors of the October 8, 2024, deadline to seek the role of lead plaintiff in a federal securities class action. The complaint alleges Moderna and its executives violated federal securities laws by making false and/or misleading statements regarding mRNA-1345's efficacy.

A Phase II trial showed AstraZeneca's Lynparza (olaparib) effective in treating recurrent prostate cancer without hormone therapy, prompting larger follow-up studies in biomarker-selected subgroups. Lynparza, a PARP inhibitor, demonstrated efficacy in patients with homologous recombination repair gene mutations, particularly BRCA2, with higher response rates than seen with hormonal suppression. The study suggests that not all prostate cancer patients need hormone therapy and highlights the need for biomarker-selected trials to identify responders.

The global pneumococcal vaccine market is projected to reach USD 12.19 billion by 2030, growing at a CAGR of 6.21% from 2024. Driven by increasing disease prevalence, government immunization programs, and new product launches, the market is dominated by the Pneumococcal Conjugate Vaccine segment, with Prevnar 13 leading in product category and the public sector in end-use. North America leads due to advanced healthcare and favorable regulations.

Upcoming webinars and presentations cover topics like the impact of Dobbs on reproductive health, clinical research glossary, health literacy, and data sharing. Publications include articles on clinical research workforce challenges, pediatric drug development during public health emergencies, and the role of institutional review boards in clinical research.

FDA approves new Pfizer and Moderna COVID-19 vaccines for fall, targeting KP.2 variant. Symptoms remain similar to previous variants, with high risk of complications. mRNA technology promotes immune response, differing from traditional vaccines. CDC recommends updated vaccine for all Americans six months and older. Limited vaccine supply available for uninsured and underinsured patients.

FDA approved updated COVID-19 vaccines targeting Omicron variants JN.1 and KP.2 for ages 12+, with mRNA vaccines by Moderna and Pfizer for ages 6 months+. CDC recommends vaccination for everyone 6 months+, emphasizing importance for high-risk groups. Timing and doses depend on vaccination status. JN.1, KP.2, KP.3, and KP.3.1.1 are circulating variants. Pharmacies like CVS and Kroger offer the vaccines.

The Global Biotechnology Market, valued at USD 1,094.6 Billion in 2024, is projected to reach USD 2772.7 Billion by 2032, with a CAGR of 14.2%. The market report includes detailed analysis, key players, and segments such as applications and technologies, with regional assessments covering North America, Europe, Asia Pacific, Latin America, and Middle East and Africa.

Moderna's updated COVID-19 vaccine targeting the JN.1 strain of Omicron receives a positive opinion from the EMA's CHMP, paving the way for marketing authorization in the EU for the 2024-2025 respiratory season.